多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究

doi:10.3969/j.issn.1004-616x.2020.06.010

癌变·畸变·突变 ›› 2020, Vol. 32 ›› Issue (6): 464-468,489.doi: 10.3969/j.issn.1004-616x.2020.06.010

多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究

丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣

河北医科大学第四医院检验科, 河北石家庄 050011

收稿日期:2020-06-11 修回日期:2020-10-20 出版日期:2020-12-01 发布日期:2020-12-04
通讯作者: 马鸣,E-mail:maming19830419@163.com E-mail:maming19830419@163.com
作者简介:丁雅雯,E-mail:dingyw19851122@126.com。
基金资助:
河北省卫健委重点课题（20201094）

Immunophenotype characteristics of plasma cells and clinical significance in multiple myeloma patients

DING Yawen, JIAO Wenjing, WANG Pengyu, LU Gang, MA Ming

Department of Clinical Laboratory, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China

Received:2020-06-11 Revised:2020-10-20 Online:2020-12-01 Published:2020-12-04

摘要/Abstract

摘要： 目的：观察多发性骨髓瘤（MM）患者骨髓中浆细胞免疫表型特点，及其与患者临床预后的相关性。方法：收集35例MM患者资料，骨髓涂片及切片分别经瑞氏-吉姆萨和HE染色后，观察分析骨髓细胞形态及病理学特点。同时，取患者骨髓或外周血分别进行流式细胞术检测及相关实验室检查。结果：MM患者骨髓浆细胞不仅数量明显增多，且形态明显异常，切片中浆细胞分布类型包括塞实型16例（45.71%），结节型14例（40.00%）和间质型5例（14.29%）。MM患者中出现血清LDH、β2-MG、Cr和BUN等检测指标升高的比例分别占80%、85.71%、62.86%和60%。MM患者浆细胞CD38、CD138均呈阳性表达，CD56、CD200、CD117和CD28阳性患者比例分别为65.71%、94.29%、60%和54.29%，CD20、CD81、CD33、CD27及CD13阳性患者比例分别为37.14%、42.86%、28.57%、57.14%和34.29%，而CD19及CD45阳性患者比例分别为22.86%和31.42%，且Igκ或Igλ链表达缺失呈单克隆增生。其中CD27和CD28的表达情况与MM患者预后密切相关，浆细胞CD27表达缺失及CD28阳性表达的患者5年总生存率较低（P < 0.05）。结论：MM患者骨髓中浆细胞免疫表型明显异常，其中CD27和CD28的表达与患者病情进展和临床预后具有显著相关性，因此免疫表型检测在MM患者临床诊断、治疗监测中具有重要意义。

关键词: 多发性骨髓瘤, 免疫表型, CD27, CD28, 预后

Abstract: OBJECTIVE: To determine immunophenotype characteristics of plasma cells in bone marrow of multiple myeloma (MM) patients and to correlate with clinical prognosis. METHODS: Bone marrow smears and sections were stained with Wright Giemsa and HE,respectively,and their morphological and pathological characteristics were analyzed. In addition,bone marrow or peripheral blood samples were collected for flow cytometry immunophenotyping and related laboratory tests. RESULTS: There was a significantly increased number of bone marrow plasma cells in MM patients and marked morphological abnormality. Their distributions included plug solid type in 16 cases (45.71%),nodular type in 14 cases (40.00%) and interstitial type in 5 cases (14.29%). Proportion of increased serum LDH,β2-MG,Cr and BUN in MM patients was 80%,85.71%,62.86% and 60%,respectively. There was positive expression of CD38 and CD138 in the plasma cells. The absence of expression of Igκor Igλ chain was monoclonal hyperplasia. The positive rates of CD56,CD200,CD117 and CD28 were 65.71%,94.29%,60% and 54.29%,respectively,and those of CD20,CD81,CD33,CD27 and CD13 were 37.14%,42.86%,28.57%,57.14% and 34.29%,respectively,as opposed to 22.86% and 31.42% in CD19 and CD45,respectively. The expressions of CD27 and CD28 were closely related to prognosis of MM patients,and the 5-year overall survival rate was lower in patients with the loss of CD27 expression in plasma cells and the positive expression of CD28 (P < 0.05). CONCLUSION: Abnormal immunophenotype was observed in plasma cells from bone marrow of MM patients,and expressions of CD27 and CD28 were significantly correlated with disease progression and prognosis. Therefore,immunophenotype detection can be of great significance in clinical diagnosis and treatment monitoring of MM patients.

Key words: multiple myeloma, immunophenotype, CD27, CD28, prognosis

中图分类号:

R733.3

丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣. 多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究[J]. 癌变·畸变·突变, 2020, 32(6): 464-468,489.

DING Yawen, JIAO Wenjing, WANG Pengyu, LU Gang, MA Ming. Immunophenotype characteristics of plasma cells and clinical significance in multiple myeloma patients[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 464-468,489.

参考文献

[1] HAMIEH M, DOBRIN A, CABRIOLU A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape[J]. Nature, 2019, 568(7750):112-116.
[2] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京:科学出版社, 2007:233.
[3] 陈辉树, 刘恩彬, 王婷婷, 等. 131例浆细胞性骨髓瘤的病理形态与临床研究[J]. 中华病理学杂志, 2004, 33(1):44-48.
[4] 刘爱宁, 陈辉树, 刘恩彬, 等. 161例慢性特发性骨髓纤维化临床病理分期的探讨[J]. 中华血液学杂志, 2006, 27(3):178-182.
[5] YU L, CHEN K, XU Y, et al. The value of EUS in combination with cytological, flow cytometry, and gene rearrangement in the diagnosis of gastrointestinal lymphoma[J]. Hematol Oncol, 2017, 35(3):303-309.
[6] MC CORMICK KA, CHEN X, WALTER RB, et al. Mott-cells[J]. Eur J Haematol, 2013, 90(1):83.
[7] MATSUE K, MATSUE Y, KUMATA K, et al. Quantification of bone marrow plasma cell infiltration in multiple myeloma:usefulness of bone marrow aspirate clot with CD138 immunohistochemistry[J]. Hematol Oncol, 2017, 35(3):323-328.
[8] VELA-OJEDA J, ESPARZA M A G R, MAJLUF-CRUZ A, et al. Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens[J]. Int J Hematol, 2019, 110(3):306-312.
[9] CHEN C C, YANG C F, YANG M H, et al. Pretreatment prognostic factors and treatment outcome in elderly patients with denovo acute myeloid leukemia[J]. Ann Oncol, 2005, 16(8):1366-1373.
[10] 唐巧云, 谢燕, 王翎, 等. 老年多发性骨髓瘤肾损害103例的临床特点[J]. 中国老年学杂志, 2011, 31(2):189-192.
[11] GAVILE C M, BARWICK B G, NEWMAN S, et al. CD86 regulates myeloma cell survival[J]. Blood Adv, 2017, 1(25):2307-2319.
[12] GOGIA A, SIKKA M, SHARMA S, et al. Hemostatic abnormalities in multiple myeloma patients[J]. Asian Pac J Cancer Prev, 2018, 19(1):127-130.
[13] UNDAS A, ZUBKIEWICZ-USNARSKA L, HELBIG G, et al. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients:association with thromboembolic complications[J]. Blood Coagul Fibrinolysis, 2015, 26(6):621-627.
[14] MCGREGOR S, MCNEER J, GURBUXANI S. Beyond the 2008 World Health Organization classification:the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia[J]. Semin Diagn Pathol, 2012, 29(1):2-11.
[15] 王慧, 刘露, 刘芳, 等. CD27抗原在多发性骨髓瘤诊断中的价值[J]. 中国实验血液学杂志, 2017, 25(4):1069-1073.
[16] YANG Q, CAO W, WANG Z, et al. Regulation of cancer immune escape:The roles of miRNAs in immune checkpoint proteins[J]. Cancer Lett, 2018, 431:73-84.
[17] MÁRK Á, VARGA G, TIMÁR B, et al. The effect of microenvironmental factors on the development of myeloma cells[J]. Hematol Oncol, 2017, 35(4):741-745.
[18] 葛芳芳, 田文亮, 孙慧敏, 等. CD28和CD117在初诊多发性骨髓瘤患者中的表达及其临床意义[J]. 白血病·淋巴瘤, 2019, 28(5):263-267.
[19] SKERGET M, SKOPEC B, ZADNIK V, et al. CD56 expression is an important prognostic factor in multiple myeloma even with bortezomib induction[J]. Acta Haematol, 2018, 139(4):228-234.

多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究

Immunophenotype characteristics of plasma cells and clinical significance in multiple myeloma patients

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[2]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[3]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[4]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[5]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[6]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[7]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[8]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[9]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.
[10]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[11]	邵俊国, 焦文静, 王雪晓, 张金艳, 马鸣. miR-429和Bmi-1 mRNA在肺癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 369-373.
[12]	吕燕萍, 吴传城, 杨双凤, 何陈周, 韩仁杰, 颜伟, 刘宝英. 胃癌差异表达miRNA及其相关基因的单核苷酸多态性与胃癌预后的相关性研究[J]. 癌变·畸变·突变, 2020, 32(5): 380-386.
[13]	郭秀娟, 杜彦艳, 颜晰, 赵学涛, 韩丽娜, 武一鹏, 王雪晓, 马鸣. CREB在食管鳞癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 387-390,394.
[14]	朱依青, 张彤彤, 郑珺文, 郝佳洁, 蔡岩, 王明荣, 梁建伟, 张钰. p-mTOR蛋白在结直肠癌组织中的表达及患者预后判断中的价值[J]. 癌变·畸变·突变, 2020, 32(3): 161-165.
[15]	杨丽, 张孟贤, 张微, 熊英友, 陈世勇, 方呈祥. 基于数据挖掘分析极光激酶A在食管癌中的表达及意义[J]. 癌变·畸变·突变, 2020, 32(3): 221-228.